Email updates

Keep up to date with the latest news and content from BMC Medicine and BioMed Central.

Journal App

google play app store
Open Access Commentary

Review of epidemiologic data on the debate over smokeless tobacco's role in harm reduction

David S Timberlake12* and Jason A Zell23

Author Affiliations

1 Program in Public Health, University of California, Irvine, Irvine, CA 92697, USA

2 Department of Epidemiology, University of California, Irvine, Irvine, CA 92697, USA

3 Division of Hematology/Oncology, Department of Medicine and Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA 92868, USA

For all author emails, please log on.

BMC Medicine 2009, 7:61  doi:10.1186/1741-7015-7-61

Published: 19 October 2009


Some tobacco researchers have argued that the European Union should remove its ban on a form of low-nitrosamine smokeless tobacco referred to as Swedish 'snus'. This argument has developed in to an international debate over the use of smokeless tobacco as a measure of harm reduction for smokers. Leading authorities in the USA have firmly stated that there is no safe tobacco - a message which does not allow for any discussion of comparative tobacco risks. This commentary is intended to review the origin of the controversy over Swedish 'snus', to examine briefly the meta-analysis on cancer risks by Peter Lee and Jan Hamling (published in July in BMC Medicine) and to discuss the anticipated direction of the debate on tobacco-harm reduction in the USA. We anticipate that much of the debate will shift from the discussion of epidemiologic data to the discussion of the marketing, health communication and economics of smokeless tobacco. While the Food and Drug Administration's newly approved authority over tobacco will undoubtedly affect the smokeless products, it may not be the sole determinant of harm reduction's fate in the USA.

See associated research article by Lee and Hamling: webcite